Theravance Biopharma, Inc.

Zymeworks Inc. announced it will report second quarter 2026 financial results on August 6, 2026, but will not host an earnings conference call due to its pending acquisition of Theravance Biopharma. The company plans to provide updates on the combined business following the expected closing of the acquisition.

Zymeworks announced a definitive agreement to acquire Theravance Biopharma for $17 per share ($929 million) to gain YUPELRI®, a nebulized LAMA for COPD treatment. The acquisition is financed through a $350 million non-recourse note from OMERS Life Sciences and Zymeworks' cash, with the deal expected to be accretive to earnings and cash flow. YUP...

The Schall Law Firm is investigating Theravance Biopharma for potential securities law violations, alleging the company issued false or misleading statements regarding its CYPRESS trial. The company reportedly spent millions on operations while the trial was in enrollment phase, resulting in significant cash burn before the trial ultimately failed.

Theravance Biopharma (NASDAQ: TBPH) shares plummeted 27.05% after its Phase 3 CYPRESS study failed to meet its primary endpoint for ampreloxetine in treating neurogenic orthostatic hypotension. The company is winding down the ampreloxetine program and implementing significant restructuring, cutting 50% of its workforce and reducing operating expe...

Irenic Capital Management LP significantly reduced its Papa John's International position by approximately 70%, selling 748,592 shares in Q4 and retaining only 325,108 shares valued at $12.5 million. The stake now represents just 0.8% of the fund's AUM, dropping out of its top five holdings. Papa John's stock has underperformed the market, declin...